Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development...

RARE : 40.55 (-1.74%)
Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up

Ultragenyx (RARE) reports a wider-than-expected loss in the second quarter. Nevertheless, revenues marginally beat estimates.

RARE : 40.55 (-1.74%)
ABEO : 2.96 (-3.90%)
SRRK : 7.08 (-1.53%)
BNTX : 133.60 (-0.14%)
Ultragenyx (RARE) Reports Q2 Loss, Tops Revenue Estimates

Ultragenyx (RARE) delivered earnings and revenue surprises of -31.40% and 0.84%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

RARE : 40.55 (-1.74%)
ANIP : 31.63 (-1.74%)
Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update

Second quarter 2022 total revenue of $89.3 million and Crysvita® revenue in Ultragenyx territories1 of $64.0 million Reaffirm 2022 Crysvita revenue in...

RARE : 40.55 (-1.74%)
Ultragenyx to Host Conference Call for Second Quarter 2022 Financial Results and Corporate Update

NOVATO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development...

RARE : 40.55 (-1.74%)
Ultragenyx (RARE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RARE : 40.55 (-1.74%)
ALNY : 209.39 (-0.65%)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development...

RARE : 40.55 (-1.74%)
Why Ultragenyx Pharmaceutical Stock Is Cratering Today

Shareholders aren't happy with the biotech's decision to acquire an early-stage asset for Angelman syndrome.

RARE : 40.55 (-1.74%)
Ultragenyx (RARE) Provides Update From Angelman Syndrome Study

Ultragenyx (RARE) and GeneTx Biotherapeutics provide an update and positive interim data from the phase I/II study on GTX-102 for treating patients with Angelman syndrome.

BEAM : 47.50 (-6.90%)
ANIK : 23.41 (-4.72%)
RARE : 40.55 (-1.74%)
FATE : 22.34 (-3.29%)
Ultragenyx and GeneTx Provide Program Update on GTX-102 for Angelman Syndrome Including Promising Interim Data from Phase 1/2 Study

Doses up to 10 mg show good tolerability and meaningful clinical activity in multiple domains U.K. and Canadian health authorities approved escalation to...

RARE : 40.55 (-1.74%)

Barchart Exclusives

A Commitment Of Traders Report With More Transparency
In a previous article, I wrote about how futures traders could find transparency in the futures market using the Legacy Commitment of Traders (COT) report. In 2009 the Disaggregated COT report started being published and has even more transparency. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar